论文部分内容阅读
目的:分析替格瑞洛与氯吡格雷对急性冠脉综合征(ACS)患者的临床疗效差异。方法:选择将我院2013年5月-2015年6月收治的90例ACS患者随机分为对照组与观察组(n=45,两组均应用阿司匹林,对照组加用氯吡格雷,实验组加用替格瑞洛,比较两组临床疗效、不良反应发生率、心血管不良事件发生率。结果:实验组患者临床总有效率为95.56%,明显高于对照组患者82.22%(P<0.05);实验组患者不良反应的发生率为4.44%,明显低于对照组患者15.60%(P<0.05);实验组心血管不良事件的发生率为2.22%,亦明显低于对照组患者13.33%(P<0.05)。结论:与氯吡格雷用药相比,应用替格瑞洛治疗急性冠脉综合征兼具临床疗效好及安全性高等优点。
Objective: To analyze the clinical effect of ticagrelor and clopidogrel in patients with acute coronary syndrome (ACS). Methods: Ninety patients with ACS who were admitted to our hospital from May 2013 to June 2015 were randomly divided into control group and observation group (n = 45, aspirin in both groups and clopidogrel in control group, experimental group Plus ticagrelor, clinical efficacy, incidence of adverse reactions, incidence of adverse cardiovascular events were compared between the two groups.Results: The total clinical effective rate was 95.56% in the experimental group, which was significantly higher than that in the control group (82.22%, P0.05 ). The incidence of adverse reactions in the experimental group was 4.44%, significantly lower than that in the control group (15.60%, P <0.05). The incidence of cardiovascular adverse events in the experimental group was 2.22%, which was significantly lower than that in the control group (13.33% (P <0.05) .Conclusion: Compared with clopidogrel, the application of ticagrelor in the treatment of acute coronary syndrome has the advantages of good clinical efficacy and high safety.